Last updated: March 2, 2026
Case Overview
Catalyst Pharmaceuticals, Inc. filed a patent infringement lawsuit against Lupin Ltd. in the District of Delaware under docket number 1:23-cv-00229. The complaint alleges Lupin’s unauthorized manufacture, use, and sale of pharmaceutical products infringing U.S. Patent No. 10,851,733, related to formulations for the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Key Facts
| Aspect |
Details |
| Filing Date |
March 2, 2023 |
| Court |
District of Delaware |
| Patent |
U.S. Patent No. 10,851,733 (issued Dec. 1, 2020) |
| Patent Holder |
Catalyst Pharmaceuticals, Inc. |
| Defendant |
Lupin Ltd. |
| Alleged Infringement |
Production and distribution of a drug product containing amifampridine for LEMS treatment, infringing asserted claims of the patent |
Patent Details
- Title: Formulations for Amifampridine
- Claim Scope: Covers specific formulations of amifampridine, including dosage forms and methods of use for treating LEMS.
- Claim Validity: Catalyst asserts the patent’s claims are valid and enforceable.
Litigation Timeline and Developments
| Date |
Event |
| March 2, 2023 |
Complaint filed, alleging infringement |
| March 10, 2023 |
Lupin files motion to dismiss, arguing claim invalidity and non-infringement |
| April 15, 2023 |
Catalyst files response opposing dismissal |
| May 22, 2023 |
Court schedules preliminary injunction hearing |
| June 15, 2023 |
Hearing held; no ruling issued yet |
| July 10, 2023 |
Lupin requests stay of proceedings pending Patent Office inter partes review (IPR) |
| August 1, 2023 |
Court grants stay pending IPR outcome |
Patent Office Proceedings
Lupin filed an IPR petition challenging the patent's validity on June 1, 2023. The Patent Trial and Appeal Board (PTAB) assigned the case as IPR2023-XXXX and has set a trial date for May 15, 2024. The IPR process could lead to claims being narrowed or invalidated, potentially affecting Catalyst’s enforcement prospects.
Legal Arguments
Catalyst's Position
- Claims are valid, enforceable, and cover Lupin’s drug formulations.
- Lupin's product infringes claim elements explicitly outlined in the patent.
- Catalyst seeks an injunction to restrain further infringement and mandatory damages for past infringement.
Lupin's Position
- Claims are invalid due to prior art references introduced in the IPR petition.
- The patent claims are indefinite or overly broad.
- Lupin’s products do not infringe as they differ in formulation details.
Potential Outcomes
- Preliminary Injunction: Court may issue an order restraining Lupin from marketing infringing products pending trial.
- Patent Validity: The IPR could revoke or limit patent claims, undermining Catalyst’s infringement case.
- Settlement: Parties may negotiate licensing or settlement to avoid lengthy litigation and IPR uncertainty.
- Final Judgment: If Catalyst prevails, damages may include injunctive relief and monetary compensation; if Lupin prevails, the patent could be invalidated.
Risk Considerations
- The outcome of the IPR remains uncertain.
- Litigation costs and potential for counterclaims or invalidity defenses.
- Patent strength, including claim scope and prior art landscape.
- Market impact if patent rights are upheld or nullified.
Industry Implications
- Enforcement of formulations for rare diseases like LEMS remains a focus for patent holders.
- Generic entry is challenged by patent litigation, affecting pricing and market dynamics.
- The outcome could influence patent strategies in neuropharmacology and orphan drug markets.
Key Takeaways
- Catalyst alleges a clear infringement of a formulation patent for amifampridine.
- Lupin's challenge via IPR could significantly diminish patent enforceability.
- The case exemplifies typical patent litigation risks in the pharmaceutical sector.
- The proceedings' resolution will impact both market competition and patent licensing strategies for LEMS treatments.
FAQs
1. What is the primary patent involved in this case?
It is U.S. Patent No. 10,851,733, covering formulations of amifampridine for LEMS.
2. What legal actions are Lupin’s defenses based on?
Challenging the patent’s validity through IPR, asserting non-infringement due to formulation differences.
3. Can a stay influence the litigation’s resolution?
Yes. The court granted a stay pending IPR outcome, potentially delaying final judgment.
4. How does IPR impact patent enforcement?
It allows the Patent Office to nullify challenged claims, weakening Catalyst's infringement case if successful.
5. What are the industry consequences of this litigation?
It emphasizes patent protection for orphan drugs and highlights risks of patent invalidity challenges.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,851,733.
- Court docket for Catalyst Pharmaceuticals, Inc. v. Lupin Ltd., No. 1:23-cv-00229 (D. Del., 2023).
